Overview

Approximately 18 months after the first patients were legally treated with MDMA and psilocybin assisted therapy, psychiatrists and psychologists working in these clinics will share reflections, learning edges, case studies and treatment outcomes. This panel will explore the therapeutic potential of psychedelics, particularly in treating mental health conditions like depression and PTSD, while also addressing the regulatory context and ethical considerations. The panel discusses areas of ongoing research, collaboration with traditional healthcare systems, the need for a comprehensive approach to ensure patient safety,  and share treatment outcomes.

Learning Outcomes

Upon completion of this event, participants should be able to:

• Have an understanding of psychedelic assisted therapy services in the community, how they operate, accessibility, regulatory matters
• Have an awareness of who makes a suitable candidate, and the potential risks and benefits of MDMA and psilocybin assisted therapy
• Understand the role of multidisciplinary teams and how they work together in psychedelic therapy clinics
• Understand the outcome data for these emerging treatments in legal community treatment centres in Australia
• Be informed of innovations in mental health care treatment that impact the psychology profession, such as psychedelic assisted therapy, and how to learn more and upskill on this emerging area

Presenter(s)

About the presenter(s)

Panel hosted by Monica Schweickle, Clinical Psychologist, psychedelic assisted therapist and Founder of the Psychedelic Consultancy: [email protected]

Panelists

• Dr. Bernadette Bywater, Clinical Psychologist, psychedelic-assisted therapist and Director of Centrepoint Psychology and Evolution 
• Mr. Mark Baxter, Psychologist and Psychedelic-assisted therapist at Evolution 
• Dr Jon Laugharne, Authorised Prescriber Psychiatrist Empax Centre
• Dr Michael Winlo, Chief Scientific Officer Emyria
• Dr Ted Cassidy, Authorised Prescriber Psychiatrist and Founder of Monarch Mental Health Group

Notes

Target Audience

This activity is aimed at psychologists and health professionals.

Duration of Access

This event will be recorded. The recording will be emailed to all registered within 2 weeks post event and available for viewing up to 90 days.

CPD

It is up to attendees to assess and determine how learning from this event aligns with the requirements of their learning plan. The providers accordingly do not make any representation that the event counts towards attendees’ CPD learning requirements. If an attendee determines themselves that the learning they complete aligns to their learning plan, then they can decide to count those hours towards their CPD requirements for the registration cycle.

The information in this presentation has been prepared in good faith and for educational purposes only. Therefore, the information is general in nature and should not be relied upon in the treatment of any condition and you should seek your own independent professional and/or legal advice concerning any specific issue. The APS accepts no responsibility for any errors, omissions or decisions relating to the information. The content should not be reproduced without permission or unless permitted by law.

If you are experiencing registration difficulties please contact APS Events Support.